NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis
- 1Department of Anesthesiology, The First Affiliated Hospital of Xi’an Medical University
- 2Chang’an University Hospital, Chang’an University
Abstract
Background: Diabetic cardiomyopathy (DCM) is a serious cardiac complication of diabetes, characterized by myocardial metabolic dysregulation, mitochondrial dysfunction, and structural remodeling. Disruption of circadian clock genes has been implicated in metabolic diseases, yet the role of neuronal PAS domain protein 2 (NPAS2), a core circadian regulator, in DCM remains poorly understood.
Methods: NPAS2 expression and circadian rhythmicity were assessed in the myocardium of T2DM and db/db mice. Cardiac-specific Npas2 knockout ( Npas2 cko ) mice were subjected to high-fat diet combined with streptozotocin (HFD + STZ) to model DCM and evaluate cardiac function, remodeling, and metabolic profiles. H9c2 cardiomyocytes were used for loss-of-function and gain-of-function experiments under high glucose/high fat (HGHF) conditions, and rescue experiments targeting pyruvate dehydrogenase (PDH) were performed to establish downstream mechanisms. Finally, adeno-associated virus serotype 9 (AAV9) mediated NPAS2 overexpression was delivered in vivo to evaluate its therapeutic potential.
Results: Myocardial NPAS2 expression was significantly reduced and its circadian oscillations were disrupted in diabetic mice. Cardiomyocyte-specific Npas2 deletion exacerbated HFD + STZ-induced cardiac dysfunction, hypertrophy, fibrosis, and lipid accumulation. In H9c2 cells, NPAS2 knockdown impaired mitochondrial respiration, increased apoptosis, elevated triglyceride and free fatty acid contents, and reduced PDH activity. Conversely, NPAS2 overexpression reversed these detrimental effects under HGHF conditions. Rescue experiments demonstrated that PDH overexpression mitigated the damage caused by NPAS2 knockdown, whereas PDH silencing abolished the protective effects of NPAS2 overexpression. In vivo , AAV9-mediated NPAS2 overexpression significantly improved cardiac function, attenuated hypertrophy and fibrosis, and restored lipid and glucose homeostasis in diabetic WT and Npas2 cko mice.
Conclusion: NPAS2 protects the heart against diabetic cardiomyopathy by maintaining PDH-dependent mitochondrial oxidative metabolism and metabolic homeostasis, representing a promising therapeutic target for DCM.
Related
- Gui Gan Shen Mai Yin attenuates cardiac hypertrophy and dysfunction in association with mitochondrial homeostasis and the PI3K/AKT1 signaling pathway
- Spermidine attenuates monocrotaline-induced pulmonary arterial hypertension with HADHA-associated improvements in fatty acid oxidation and mitochondrial redox homeostasis
- Niosomal Mexiletine Attenuates Rotenone-Induced Parkinsonism via Modulation of the circDLGAP4/miR-134-5p/p-CREB Axis and Restoration of Mitochondrial-Autophagic Homeostasis.
- Oral administration of Angiotensin-(1-7) included in hydroxypropyl β-cyclodextrin attenuates cardiac hypertrophy and inflammation in a mouse model of Takotsubo cardiomyopathy
- NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria
BibTeX
@article{li2026npas2,
title = {{NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis}},
author = {Wenjiao Li and Bin Han and Di Zhu and Lixia Luan and Xuyun Dang},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1980726},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1980726/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis
AU - Wenjiao Li
AU - Bin Han
AU - Di Zhu
AU - Lixia Luan
AU - Xuyun Dang
PY - 2026
DA - 2026/10/19
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1980726
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1980726/full
AB - Background: Diabetic cardiomyopathy (DCM) is a serious cardiac complication of diabetes, characterized by myocardial metabolic dysregulation, mitochondrial dysfunction, and structural remodeling. Disruption of circadian clock genes has been implicated in metabolic diseases, yet the role of neuronal PAS domain protein 2 (NPAS2), a core circadian regulator, in DCM remains poorly understood. Methods: NPAS2 expression and circadian rhythmicity were assessed in the myocardium of T2DM and db/db mice. Cardiac-specific Npas2 knockout ( Npas2 cko ) mice were subjected to high-fat diet combined with streptozotocin (HFD + STZ) to model DCM and evaluate cardiac function, remodeling, and metabolic profiles. H9c2 cardiomyocytes were used for loss-of-function and gain-of-function experiments under high glucose/high fat (HGHF) conditions, and rescue experiments targeting pyruvate dehydrogenase (PDH) were performed to establish downstream mechanisms. Finally, adeno-associated virus serotype 9 (AAV9) mediated NPAS2 overexpression was delivered in vivo to evaluate its therapeutic potential. Results: Myocardial NPAS2 expression was significantly reduced and its circadian oscillations were disrupted in diabetic mice. Cardiomyocyte-specific Npas2 deletion exacerbated HFD + STZ-induced cardiac dysfunction, hypertrophy, fibrosis, and lipid accumulation. In H9c2 cells, NPAS2 knockdown impaired mitochondrial respiration, increased apoptosis, elevated triglyceride and free fatty acid contents, and reduced PDH activity. Conversely, NPAS2 overexpression reversed these detrimental effects under HGHF conditions. Rescue experiments demonstrated that PDH overexpression mitigated the damage caused by NPAS2 knockdown, whereas PDH silencing abolished the protective effects of NPAS2 overexpression. In vivo , AAV9-mediated NPAS2 overexpression significantly improved cardiac function, attenuated hypertrophy and fibrosis, and restored lipid and glucose homeostasis in diabetic WT and Npas2 cko mice. Conclusion: NPAS2 protects the heart against diabetic cardiomyopathy by maintaining PDH-dependent mitochondrial oxidative metabolism and metabolic homeostasis, representing a promising therapeutic target for DCM.
SN - 2297-055X
ER -